So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Watch excerpts from this Patheon-sponsored super session at BIO International, as Steve Lam presents, “So Many Choices: What’s the Right Biomanufacturing Strategy for Me?”

Author: Steve Lam, Senior VP Biologics

Related Sites

Additional Resources

Global steriles investment & innovation

Steriles Drug Development & Manufacturing: Flexibility and Optimization

Growing Your Biopharma: Ten Questions You're Likely to Face From Investors—And How to Respond to Them

5,000L single-use bioreactors: The next generation in biologics manufacturing

A Tale of Two CDMOs: Which Choice Will Your Biopharma Make?

CDMO Timebombs: Five Ways the Wrong Partner Can Lead to Trouble Down the Road

Navigating the Adoption of Continuous Manufacturing Amid Unprecedented Global Challenges

Impact of a Pandemic Outbreak on Vaccine Development Approach

Analytical Considerations For Biopharmaceuticals During Commercialization

Small Pharma, Big Opportunity Infographic

Validation or Qualification - What's the difference?

Benefits of 5KL Bioreactor When Outsourcing Late-phase Biologics Drug Substance Manufacturing

Practical Implementation of Innovative and Scalable Technologies to Accelerate Biologics Development and Commercialization: A CDMO Perspective

Saving Development Time with Single Vendor Approach

Leveraging Infrastructure Investments and Innovation to Accelerate Biologics Development

Accelerating Cell Culture Development through Practical Application of Innovation Technologies

Leveraging Innovative Technologies, Best Practices and Strategies to Accelerate Biologics Development and Commercialization

Biologics Overview

Quick to Clinic™ Delivers Phase I Clinical Trial Material, Fast

Continuous Manufacturing: The Alternative to Batch Manufacturing

Challenges and Practical Solutions for Changing Over to Pre-filled Syringes for Parenteral Drug

Continuous Manufacturing: Drug Development Workflow and Benefits

What You Need to Know About Process Characterization and Validation For Biologic Processes

Continuous or Batch: Deciding on the Best Solution for your Oral Solid Dose Product

Telltale Signs You're with the Wrong CDMO

Choosing the Right CDMO for Late Phase Clinical Trials

Process Characterization: Ready For The FDA?

Biopharma Capabilities Overview

How Pacira Pharma Is Working To Help Curb The Opioid Epidemic

Collegium Pharmaceutical’s Approach to Abuse Deterrence Breaks New Ground

Fighting The Opioid Epidemic: How Grünenthal’s Abuse-Deterrent Technology Contributes

Pharma Services Overview Brochure

In-House Versus Outsource: A Decision-Making Guide

Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing

Biologics Overview: Flexible Biomanufacturing Solutions

So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Case Study: Curbing the Opioid Epidemic with Pacira Pharmaceuticals

Choosing the Best Biomanufacturing Strategy: The Value of a Multi-Pronged Approach

Technology Transfers: Reaping Rewards, Reducing Risks

Decision Timeline: Considerations in Selecting an Outsourced Solution

Is Your In-House Strategy Ready for the Uncertainties of Biologic Drug Development?

Managing Demand Uncertainty in Biologics Production

How Adaptable Manufacturing Models are Paving a Steady Path into an Unpredictable Future

Top 5 Considerations When Looking to Outsource to a Biomanufacturing Partner

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

Consultants’ Guide to Flexible Biomanufacturing Solutions

Top Five Risks Facing Your Small Biopharma Clients Today

Challenges, Risks, and Strategies for Biologic Substance Manufacturing

Solving the OOS Problem with Continuous Manufacturing

Impact of Incorrect Forecasts on New Product Launches

Solutions to Today’s Biomanufacturing Challenges

Multiplexing: Managing Risk with Proven, Single-Use Solutions

Executive Research: Impact of Incorrect Forecasts on New Product Launches

Built To Fail: How Today's Manufacturing Options Leave Pharma At Risk